Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Cerenome Earnings Call: Key Takeaways

Cerenome is transitioning to a commercial-stage entity with CNSide diagnostic revenue scaling and Rheobic radiopharmaceutical trials meeting key safety and enrollment milestones for 2027 readouts.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthDiagnostic revenue $0.7M; gross charges $1.55M from 222 tests in Q3.
Mgmt ConfidenceConfident in breaking Phase 1 radiation ceilings without dose-limiting toxicities.
Demand Visibility34 institutions in onboarding backlog; 190 million total covered lives reached.
Order Book512 tumor cell tests year-to-date; 26 institutions and 45 providers ordering.
Margin TrendsCost of revenue $0.9M against $0.7M revenue; diagnostic burn $10M annually.
Op. LeverageExpect testing and collections to materially offset cash burn by H2 2027.
Pricing PowerAetna national agreement includes contracted rates for cell enumeration and profiling.
Vol vs PriceGrowth driven by new accounts, patient monitoring, and expanded test menu.
Segment GrowthDiagnostics scaling; Therapeutics (Rheobic) in Phase 2 with mid-2027 data expected.
New ClientsAdded Aetna national contract; 100 signed access agreements awaiting conversion.
Capex & DebtEnded September with $4.9M cash; accessed $20M royalty/financing facility.
RegulatoryMedicare reimbursement tracking for H1 2027; FDA aligned on dose optimization.
CommentaryStrategic focus on 'compounding' adoption, monitoring frequency, and menu expansion per specimen.
New LaunchesLaunched CSF molecular profile October 12; breast cancer assays launching 2027.

Growth

Diagnostic revenue was $0.7M; October test volume grew 15% over Q3 average.

Outlook

Targeting $10M-$12.5M annualized gross billing run rate exit 2026; doubling in 2027.

Risks

Management pivoted to gross billings instead of revenue guidance due to lack of collection history.

Source

The company's earnings call, NASDAQ: CNSY, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Cerenome, Inc.: key numbers

Share price
$0.7148Close, Nov 16
Market cap
$6.99M
Shares outstanding
9.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cerenome, Inc.

All →
7:45 AM ET 8-K
Clinical Trial Data

Cerenome Clinical Trial Data

Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.

Counterparty
Society for Neuro-Oncology
5:07 PM ET 10-Q
Financial Results ▶ Call

Cerenome Q3 2026 Results: Net Loss of $8.66M, Loss Widens

Cerenome, Inc. reported a net loss of $24.6 million for the nine months ended September 30, 2026, compared to a $16.7 million loss in the prior year period. While the company introduced diagnostic revenue of $0.7 million, total revenue decreased due to lower grant revenue, and operating expenses nearly doubled to $25.8 million.

Key figure
Net loss $8.66M
4:52 PM ET 8-K
Financial Results

Cerenome Financial Results

Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.

Term
Q3 2026

“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”

Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
6:01 AM ET 8-K
Executive Compensation

Cerenome Executive Compensation

Cerenome, Inc. appointed Ronald A. Andrews as its new Chief Business Officer, effective November 9, 2026. Mr. Andrews, who already serves on the company's board, entered into an employment agreement providing for an annual base salary of $344,955, a 43% target bonus, and an option to purchase 92,858 shares of common stock.

Counterparty
Ronald A. Andrews
7:31 AM ET 8-K
Investor Presentation

Cerenome Investor Presentation

Cerenome, Inc. (formerly Plus Therapeutics, Inc.) filed an updated corporate presentation as of September 30, 2026, for use in meetings with investors and analysts. The presentation covers the company's clinical trials, strategic collaborations, and the development of its CNSide platform for genomic testing.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.